UK-based pharmaceutical company AstraZeneca has received more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) to develop, manufacture and deliver a Covid-19 vaccine developed by the University of Oxford.
Last month, AstraZeneca signed an agreement with the University of Oxford to develop and distribute the university’s Covid-19 vaccine candidate, ChAdOx1 nCoV-19.
Go deeper with GlobalData
The company has now finalised its licence agreement for the recombinant adenovirus vaccine, renamed AZD1222. In addition, the company has committed to supporting the formation of a joint research centre at Oxford University focused on pandemic preparedness research.
